GlassScriptPhysician profile
Ajay Mathew
NPI 1346528296
$4,519.69
in general payments reported to CMS, 2019-2025
27 companies · $940 in 2025
The $940 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $87.71 · 2021: $295 · 2022: $737 · 2023: $1,162 · 2024: $1,076 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134 · Education: $43.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,134.26 |
| Education | $43.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $990.41 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $577.27 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $388.81 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $303.07 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $267.02 | 2022-2025 | Acthar, Terlivaz |
| Horizon Therapeutics Plc | $186.93 | 2020-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $183.90 | 2023-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.95 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $178.46 | 2019-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $169.34 | 2023-2025 | |
| Ardelyx, INC. | $160.92 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $146.49 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $139.17 | 2022-2024 | Benlysta |
| Renalytix Ai, INC. | $129.38 | 2022-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Amgen INC. | $116.52 | 2022-2025 | Krystexxa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $76.76 | 2019-2025 | Velphoro, Crit-Line, 2008t Bluestar Hemodialysis Machine |
| Scpharmaceuticals INC. | $53.31 | 2025 | |
| Baxter Healthcare | $48.25 | 2020-2023 | Renal - Pd |
| Vifor Pharma, INC. | $41.89 | 2019-2022 | |
| Travere Therapeutics, INC. | $37.90 | 2023-2024 | |
| Mallinckrodt Enterprises LLC | $31.84 | 2019 | |
| Mannkind Corporation | $27.48 | 2025 | |
| Novo Nordisk INC | $24.52 | 2025 | Ozempic |
| Kyowa Kirin, INC. | $21.40 | 2024 | Crysvita |
| Bard Peripheral Vascular, INC. | $16.69 | 2024 | |
| Arbor Pharmaceuticals, INC. | $11.74 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.